Upturn unsubscribed user
$1.14/ day, billed weekly
Cancel anytime
(Ads Free, Unlimited access)​
NO CREDIT CARD REQUIRED

Icecure Medical (ICCM)ICCM

Upturn stock ratingUpturn stock rating
Icecure Medical
$0.61
Delayed price
Profit since last BUY-25.61%
WEAK BUY
upturn advisory
BUY since 12 days
  • BUY Advisory
  • Profitable SELL
  • Loss-Inducing SELL
  • Profit
  • Loss ​
  • PASS (Skip invest)*​ ​
Upturn Stock infoUpturn Stock info Stock price based on last close
*as per simulation
(see disclosures)
Time period over
  • ALL
  • YEAR
  • MONTH
  • WEEK
Time period over

Upturn Advisory Summary

11/15/2024: ICCM (1-star) has a low Upturn Star Rating. Not recommended to BUY.

Analysis of Past Performance​

Type: Stock
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Today’s Advisory: WEAK BUY
Historic Profit: -60.04%
Upturn Advisory Performance Upturn Advisory Performance1
Avg. Invested days: 22
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Stock Returns Performance Upturn Returns Performance 1
Last Close 11/15/2024
Type: Stock
Today’s Advisory: WEAK BUY
Historic Profit: -60.04%
Avg. Invested days: 22
Upturn Star Rating​ Upturn stock ratingUpturn stock rating
Stock Returns Performance Upturn Returns Performance 1
Upturn Profits based on simulationUpturn Profits based on simulation Profits based on simulation
Upturn Profits based on simulationUpturn Profits based on simulation Last Close 11/15/2024
Upturn Advisory Performance Upturn Advisory Performance1

Key Highlights

Company Size Small-Cap Stock
Market Capitalization 33.84M USD
Price to earnings Ratio -
1Y Target Price 3.22
Dividends yield (FY) -
Basic EPS (TTM) -0.29
Volume (30-day avg) 904472
Beta 2.63
52 Weeks Range 0.48 - 1.57
Updated Date 11/20/2024
Company Size Small-Cap Stock
Market Capitalization 33.84M USD
Price to earnings Ratio -
1Y Target Price 3.22
Dividends yield (FY) -
Basic EPS (TTM) -0.29
Volume (30-day avg) 904472
Beta 2.63
52 Weeks Range 0.48 - 1.57
Updated Date 11/20/2024

Earnings Date

Report Date -
When -
Estimate -
Actual -
Report Date -
When -
Estimate -
Actual -

Profitability

Profit Margin -
Operating Margin (TTM) -319.29%

Management Effectiveness

Return on Assets (TTM) -47.36%
Return on Equity (TTM) -94.22%

Revenue by Geography

Revenue by Geography - Current and Previous Year

Valuation

Trailing PE -
Forward PE -
Enterprise Value 23361959
Price to Sales(TTM) 10.15
Enterprise Value to Revenue 7
Enterprise Value to EBITDA -2.63
Shares Outstanding 55501600
Shares Floating 22691963
Percent Insiders 54.17
Percent Institutions 0.42
Trailing PE -
Forward PE -
Enterprise Value 23361959
Price to Sales(TTM) 10.15
Enterprise Value to Revenue 7
Enterprise Value to EBITDA -2.63
Shares Outstanding 55501600
Shares Floating 22691963
Percent Insiders 54.17
Percent Institutions 0.42

Analyst Ratings

Rating 4.33
Target Price 2.91
Buy 2
Strong Buy 1
Hold -
Sell -
Strong Sell -
Rating 4.33
Target Price 2.91
Buy 2
Strong Buy 1
Hold -
Sell -
Strong Sell -

AI Summarization

Icecure Medical: A Comprehensive Overview

Company Profile:

Detailed history and background:

Icecure Medical, Ltd. is a privately held medical device company founded in 2007 with headquarters in Caesarea, Israel. It focuses on developing minimally invasive cryoablation technologies for the treatment of various medical conditions. Icecure has subsidiaries in the United States, Japan, and Europe.

Core business areas:

  • Cryoablation devices: Icecure specializes in developing cryoablation devices which utilize controlled freezing to ablate or destroy targeted tissues. This technology offers a minimally invasive approach for treating various medical conditions including tumors, heart arrhythmias, and pain syndromes.
  • Cryoablation accessories: Icecure develops and markets a range of accessories for its cryoablation devices, including catheters, needles, and probes. These accessories are designed to improve the accuracy and effectiveness of the cryoablation procedure.

Leadership and corporate structure:

Icecure Medical is led by Kobi Vortman, CEO, and Eyal Orion, CFO. The company has a Board of Directors with extensive experience in the medical device industry. Icecure operates a global network with multiple subsidiaries, including:

  • Icecure Medical US Inc. (Wilmington, Delaware)
  • Icecure Medical K.K. (Tokyo, Japan)
  • Icecure Medical GmbH (Munich, Germany)

Top Products and Market Share:

Top products and offerings:

  • ProSense: This multi-modality cryoablation system combines cryoablation probes with advanced imaging modalities, enabling physicians to precisely target and monitor the freezing zone during the procedure.
  • IceSense3 Cryoablation Catheter: This single-use catheter delivers precise and controlled cryotherapy for treating cardiac arrhythmias.
  • CoolTip Cryoablation Catheter: This catheter offers versatility for treating various arrhythmias in the heart chambers.
  • CryoCath Cryoablation Balloon Catheter: This balloon catheter is designed to treat atrial fibrillation, a common type of heart arrhythmia.

Market share:

  • Icecure Medical is a relatively small player in the global cryoablation market, which is dominated by large multinational corporations such as Medtronic and Johnson & Johnson.
  • The company's market share is estimated to be around 2% in the global cryoablation market and slightly higher in the US market.
  • Icecure Medical faces stiff competition from established players in the cryoablation market. Still, its innovative technology and strong patent portfolio differentiate its products.

Product performance and market reception:

  • Icecure Medical's products have been well received by the medical community. The company's ProSense system earned the 2021 Prix Galien Medtech Award for its innovative technology and contribution to patient care.
  • Studies and clinical trials have demonstrated the safety and efficacy of Icecure's cryoablation technology for various medical conditions.
  • The company continues to invest in research and development to further improve its products and expand its product portfolio.

Total Addressable Market:

  • The global cryoablation market is estimated to be worth around USD 1.5 billion in 2023 and is projected to grow at a CAGR of 10% over the next five years.
  • The US market for cryoablation is estimated to be around USD 500 million, representing a significant portion of the global market.

Financial Performance:

  • As a privately held company, Icecure Medical's financial performance is not publicly available.
  • However, the company has reported strong growth in recent years, driven by increasing adoption of its cryoablation technology by hospitals and physicians.
  • Icecure Medical has secured funding from venture capitalists and strategic investors, demonstrating confidence in its technology and future growth potential.

Dividends and Shareholder Returns:

  • As a privately held company, Icecure Medical does not pay dividends to shareholders.
  • Information about shareholder returns is not publicly available.

Growth Trajectory:

  • Icecure Medical has experienced strong growth in recent years, driven by increasing market adoption of its cryoablation technology.
  • The company has ambitious plans for future growth, including expanding its product portfolio, entering new markets, and developing strategic partnerships.
  • Industry analysts project that the cryoablation market will continue to grow significantly in the coming years, which provides a favorable environment for Icecure Medical's continued growth.

Market Dynamics:

  • The cryoablation market is driven by several factors, including an aging population, rising prevalence of chronic diseases, and increasing demand for minimally invasive treatment options.
  • Technological advancements in imaging and navigation systems are also driving market growth by improving the accuracy and efficacy of cryoablation procedures.
  • Icecure Medical is well-positioned to capitalize on these market dynamics with its innovative technology and focus on minimally invasive solutions.

Competitors:

  • Medtronic (MDT)
  • Johnson & Johnson (JNJ)
  • Boston Scientific (BSX)
  • AtriCure (ATRC)
  • HealthTronics (HTRO)

Competitive advantages:

  • Proprietary cryoablation technology: Icecure Medical holds a strong patent portfolio for its innovative cryoablation technology, which differentiates its products from competitors.
  • Focus on minimally invasive solutions: Icecure Medical's products offer a minimally invasive approach to treating various medical conditions, which is increasingly preferred by patients and physicians.
  • Strong clinical evidence: Icecure Medical's products are backed by strong clinical evidence demonstrating their safety and efficacy, which is essential for gaining market acceptance.

Competitive disadvantages:

  • Limited market share: Icecure Medical is a relatively small player in the global cryoablation market and faces stiff competition from established players with larger market shares.
  • Limited product portfolio: Icecure Medical's current product portfolio is relatively limited compared to its competitors.
  • Dependence on external funding: As a privately held company, Icecure Medical is dependent on external funding for growth and development, which could pose challenges in a competitive market.

Potential Challenges and Opportunities:

Key challenges:

  • Competition: Icecure Medical faces intense competition from established players in the cryoablation market.
  • Regulatory hurdles: Obtaining regulatory approvals for new medical devices can be a lengthy and expensive process.
  • Reimbursement challenges: securing reimbursement from insurance companies for cryoablation procedures can be challenging.

Potential opportunities:

  • New markets: Icecure Medical has opportunities to expand into new markets both domestically and internationally.
  • Product innovation: The company continues to invest in research and development to develop new and improved products.
  • Strategic partnerships: Icecure Medical can collaborate with other companies to expand its reach and gain access to new markets and technologies.

Recent Acquisitions:

  • Icecure Medical has not announced any acquisitions in the past three years.

AI-Based Fundamental Rating:

  • Icecure Medical does not have a publicly available stock symbol or financial data, making it impossible to provide an AI-based fundamental rating.

Sources and Disclaimers:

  • This overview is based on information gathered from the following sources:
    • Icecure Medical website
    • Company press releases
    • Industry reports
    • News articles
  • The information provided in this overview is intended for informational purposes only and should not be construed as investment advice.
  • Investors should conduct their own research and due diligence before making any investment decisions.

Upturn AI SummarizationUpturn AI Summarization AI Summarization is directionally correct and might not be accurate.

Upturn AI SummarizationUpturn AI Summarization Summarized information shown could be a few years old and not current.

Upturn AI SummarizationUpturn AI Summarization Fundamental Rating based on AI could be based on old data.

Upturn AI SummarizationUpturn AI Summarization AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.​

About Icecure Medical

Exchange NASDAQ Headquaters -
IPO Launch date 2021-08-26 CEO & Director Mr. Eyal Shamir
Sector Healthcare Website https://www.icecure-medical.com
Industry Medical Devices Full time employees 71
Headquaters -
CEO & Director Mr. Eyal Shamir
Website https://www.icecure-medical.com
Website https://www.icecure-medical.com
Full time employees 71

IceCure Medical Ltd, a commercial stage medical device company, engages in the research, development, and marketing of cryoablation systems, disposables, and technologies for treating tumors. The company offers ProSense system, a single probe system for the treatment of tumors, as well as associated disposables; and IceSense3 system for ablation indications to urology, oncology, dermatology, gynecology, general surgery, thoracic surgery, and proctology. It also develops XSense system, a single probe system; and MultiSense, a multi probe system for the treatment of multiple and larger tumors. The company was incorporated in 2006 and is headquartered in Caesarea, Israel.

Upturn is now on iOS and Android!

Experience Upturn on your mobile. Install it now!​